文献速递血管炎

粒细胞集落刺激因子相关大血管炎罕见需糖皮质激素:日本癌症中心队列

Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

19例中18例(94.7%)未用糖皮质激素治疗,全部达到缓解;仅1例因肾功能不全接受2周糖皮质激素。结论认为G-CSF相关LVV的免糖皮质激素管理可能安全有效。

要点

  • G-CSF相关LVV发生率0.4%(19/4708),以乳腺癌和聚乙二醇非格司亭为主。
  • 18例未用糖皮质激素者(15例NSAIDs、1例对乙酰氨基酚、2例观察)全部缓解。
  • 末次G-CSF至LVV起病中位7天,至缓解中位30天,影像学缓解中位51天。

核心结论

  • G-CSF相关LVV的免糖皮质激素管理可能安全有效,多数患者无需糖皮质激素即可缓解。

主要发现

  • G-CSF相关LVV发生于4708例中的19例(0.4%),中位年龄64岁(范围53-79),女性占73.7%。
  • 乳腺癌最常见(36.8%),聚乙二醇非格司亭最常用(94.7%)。
  • 19例中18例(94.7%)接受非糖皮质激素治疗:15例(78.9%)NSAIDs、1例(5.3%)对乙酰氨基酚、2例(10.5%)观察,全部缓解(100%)。
  • 1例因肝功能障碍停用NSAIDs,未观察到严重不良事件;另1例(5.3%)因肾功能不全接受糖皮质激素2周。
  • 末次G-CSF至LVV起病、炎症峰值、缓解及影像学缓解的中位间隔分别为7天(范围2-15)、14天(10-19)、30天(14-49)和51天(27-346)。

临床怎么用

  • 对G-CSF相关LVV可优先考虑NSAIDs等免糖皮质激素管理,仅在NSAIDs反应不足或不耐受时使用糖皮质激素。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy of glucocorticoid-sparing management in patients with G-CSF-associated large-vessel vasculitis (LVV). METHODS: Patients with cancer diagnosed with LVV following G-CSF administration between April 2020 and December 2024 were included. Patients received non-glucocorticoid treatment, mainly NSAIDs, whereas those with an inadequate response to or intolerance of NSAIDs were treated with glucocorticoids. The primary outcome was the remission rate in patients treated without glucocorticoids. RESULTS: G-CSF-associated LVV occurred in 19 of 4708 patients (0.4%). The median age was 64 years (range: 53-79), and 73.7% were females. Breast cancer was the most common cancer type (36.8%). Pegfilgrastim was the most frequently used agent (94.7%). Of the 19 patients, 18 (94.7%) received non-glucocorticoid treatment: 15 (78.9%) with NSAIDs, one (5.3%) with acetaminophen and two (10.5%) under observation, all achieving remission (100%). NSAIDs were discontinued in one patient owing to liver dysfunction; however, no serious adverse events were observed. Another patient (5.3%) with renal dysfunction received glucocorticoids for 2 weeks. The median intervals from the last G-CSF administration to LVV onset, peak inflammation, remission and imaging remission were 7 (range: 2-15), 14 (10-19), 30 (14-49) and 51 (27-346) days, respectively. Filgrastim was subsequently administered to five patients (26.3%) who developed LVV following pegfilgrastim administration. All patients achieved remission and experienced no recurrence regardless of treatment. CONCLUSION: Glucocorticoid-sparing management of G-CSF-associated LVV may be a safe and effective approach.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Morita Y, Takeda K, Osumi H, et al. Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort. Rheumatology (Oxford). 2026. PMID: 41390923. doi:10.1093/rheumatology/keaf678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。